Show simple item record

The Evolution of Antisense Oligonucleotide Chemistry - A Personal Journey

dc.contributor.authorAgrawal, Sudhir
dc.date2022-08-11T08:10:00.000
dc.date.accessioned2022-08-23T16:51:41Z
dc.date.available2022-08-23T16:51:41Z
dc.date.issued2021-05-03
dc.date.submitted2021-08-26
dc.identifier.citation<p>Agrawal S. The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey. Biomedicines. 2021 May 3;9(5):503. doi: 10.3390/biomedicines9050503. PMID: 34063675; PMCID: PMC8147625. <a href="https://doi.org/10.3390/biomedicines9050503">Link to article on publisher's site</a></p>
dc.identifier.issn2227-9059 (Linking)
dc.identifier.doi10.3390/biomedicines9050503
dc.identifier.pmid34063675
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41907
dc.description.abstractOver the last four decades, tremendous progress has been made in use of synthetic oligonucleotides as therapeutics. This has been possible largely by introducing chemical modifications to provide drug like properties to oligonucleotides. In this article I have summarized twists and turns on use of chemical modifications and their road to success and highlight areas of future directions.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34063675&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectantisense
dc.subjectmedicinal chemistry
dc.subjectoligonucleotide
dc.subjectstructure activity relationship
dc.subjecttherapeutic
dc.subjectBiochemistry
dc.subjectMedicinal and Pharmaceutical Chemistry
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectNucleic Acids, Nucleotides, and Nucleosides
dc.subjectTherapeutics
dc.titleThe Evolution of Antisense Oligonucleotide Chemistry - A Personal Journey
dc.typeJournal Article
dc.source.journaltitleBiomedicines
dc.source.volume9
dc.source.issue5
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5747&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4714
dc.identifier.contextkey24508966
refterms.dateFOA2022-08-23T16:51:41Z
html.description.abstract<p>Over the last four decades, tremendous progress has been made in use of synthetic oligonucleotides as therapeutics. This has been possible largely by introducing chemical modifications to provide drug like properties to oligonucleotides. In this article I have summarized twists and turns on use of chemical modifications and their road to success and highlight areas of future directions.</p>
dc.identifier.submissionpathoapubs/4714
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases And Immunology
dc.source.pages503


Files in this item

Thumbnail
Name:
biomedicines_09_00503.pdf
Size:
1.437Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as Copyright © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).